Sou Hu Cai Jing·2025-07-28 11:04Company Overview - Zhao Yan New Drug closed at 32.0 yuan, up 7.02%, with a rolling PE ratio of 61.91, the lowest in 488 days, and a total market value of 23.983 billion yuan [1] - The company specializes in non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1] Financial Performance - For Q1 2025, the company reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit was 41.1195 million yuan, a year-on-year increase of 115.11%, with a gross margin of 28.61% [1] Shareholder Information - As of September 30, 2020, the number of shareholders was 17,882, a decrease of 783 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical services industry is 48.04, with a median of 58.89, placing Zhao Yan New Drug at 30th in the industry ranking [1][2] - The static PE ratio for Zhao Yan New Drug is 32.77, with a price-to-book ratio of 2.96 [2]